Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today's Pharmaceutical Executive Daily, a commentary examines why fragmented software tooling causes scientific judgment to get lost across the biologics R&D pipeline, Replimune shares crash nearly 32 percent after FDA reviewers raise concerns about its melanoma therapy, and FDA approves Viatris's Gwyn Lo as a new once-weekly contraceptive patch. FDA has approved Viatris's Gwyn Lo, a once-weekly transdermal contraceptive patch delivering low-dose norelgestromin and ethinyl estradiol, for women with a body mass index below 30 who are candidates for combined hormonal contraception. Viatris expects Gwyn Lo to be commercially available later this year. Thanks for listening to Pharmaceutical Executive Daily.